Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
NCT07489599Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of QLH2405 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (17 cohorts), sponsored by Qilu Pharmaceutical. Primary endpoint: Adverse Events. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
QLH2405
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07489599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07489599.